Is the Melkersson-Rosenthal syndrome related to the exposure to food additives? A case report.

We present a case of Melkersson-Rosenthal syndrome that occurred in an adult patient who experienced intolerance to the food additives sodium benzoate and tartrazine. The main symptoms were the facial swelling, hypertrophy of the gums, and a typical infiltration of lymphocytes and plasma cells around the small vessels observed in the biopsy of the gums. No involvement of facial nerves was present, and other disorders of granulomatosis have been excluded. All clinical manifestations went into remission once the food additives were excluded from the usual diet.

[Pseudohypoparathyroidism associated with hyperaldosteronism and polyglobulia]. / Pseudoipoparatiroidismo associato a iperaldosteronismo e poliglobulia.

A new case of familial PHP, associated with polyglobulia and biochemical parameters of hyperaldosteronism has been described. This association represents a very rare entity. PHP has been documented by the common tests and the unresponsiveness of AMPc to PTH. The poliglobulia , which appears after a period of severe anaemia, needs now periodical blood subtraction; nevertheless a cerebral thrombosis with conseguent hemiparesis has recently occurred. The hyperaldosteronism has been documented by hypopotassiemia , a raised level of plasma aldosterone as well as suppressed plasma renin activity even after adequate stimulus.

[Behçet's syndrome. Description of a clinical case]. / Sindrome di Behçet. Descrizione di un caso clinico.

We present a case of a young man hospitalized for a fever and bipolar aphtous. The absence of typical ocular lesions, the delayed occurrence of thromboflebitis, arthritis, abnormal skin reactivity, as well as the presence of splenomegaly and limphoadenopathy, induced us to consider a large variety of infection disease before the diagnosis of Behçet's Syndrome. The complete remission has been achieved with corticosteroids and Laevamisole (150 mg/weekly). No therapy has been necessary in the last twelve months.

Serum folate binding capacity in patients with solid tumors.

Total and unsaturated folate binding capacity (TFBC-UFBC) was measured in 44 normal volunteers and in 77 patients with solid tumors; of them 31 had a lung cancer, 18 a cancer of the gastrointestinal tract (GI), and 28 a breast cancer. With the exception of patients with cancer of the stomach, all the other groups showed a significant increase in TFBC. An increase in UFBC was statistically observed in patients with lung cancer and cancer of the GI tract. No correlation was observed in breast cancer between the presence of hormone receptors on cancer tissue and the value of TFBC. However, a significant increase in TFBC was noted in this group of patients when metastases were present.

Evidence for a folic acid binding protein in human cell membrane.

Cell membranes were prepared by sucrose discontinuous gradient from human liver and human peripheral leukocytes and erythrocytes and from circulating leukocytes from patients with chronic granulocytic leukemia (CGL) and acute myeloblastic leukemia (AML). The membrane preparations from liver and from leukemic leukocytes were shown to bind tritiated folic acid. The membranes from normal leukocytes and erythrocytes did not show this binding capacity. The membrane preparation from liver and CGL leukocytes showed two peaks of binding eluting with proteins from Sephadex G-200. However, protein extracts of these membrane preparations showed only a single peak for labelled folic acid, eluting near but just after albumin. The binding capacity of the membranes for folic acid was partially inhibited by reduced folate analogues. It is concluded that the liver plasma cell membrane and the membranes of myeloblasts in AML and circulating leukocytes in CGL contain a binding protein for folic acid which may be concerned in the transport of folates into these cells.

Different binding proteins for folic acid in serum of patients with acute hepatitis.

Serum from 44 volunteers and 21 patients with acute hepatitis and 18 with cirrhosis were tested for the total and unsaturated folate binding capacity (TFBC-UFBC). A high level of TFBC was noted in acute hepatitis (p < 0.001) and in cirrhosis (p < 0.05), whereas only in the last case a reduced UFBC was present (p < 0.05). When serum from patients with acute hepatitis was eluted on Sephadex G-200 after incubation with radio-active folic acid (500 pg), two main peaks were observed, one in the exclusion peak of protein and the second in the position of the only binder found in normal serum (MW 43,000). A third small peak was also present in the position corresponding to a MW of 20,000. These findings documented the release of binders from hepatic cell when a massive necrosis of liver occurs.

Serum folate binding capacity in leukemias, liver diseases and pregnancy.

Total and unsaturated folate binding capacity (TFBC, UFBC) have been measured in sera of selective groups of patients to study the role of cell turnover, cell necrosis and the effect of pregnancy in determining their concentrations in blood. The mean value of TFBC in 35 normal sera was 151 +/- (SD) 53 pg/ml with a saturation of 88%. The TFBC was raised in chronic granulocytic leukemia (CGL), in acute hepatitis, in cirrhosis, and in pregnancy (third trimester). The normal mean value of TFBC was found in chronic lymphocytic leukemia (CLL) and inthe first trimester of pregnancy. The mean UFBC in the normal sera was 19 +/- 18 pg/ml. In all the pathological conditions studied the mean UFBC was significantly greater than normal and it was particularly high in CGL (85 +/- 78 pg/ml).

Specific and non-specific folate binding protein in normal and malignant human tissues.

Binding of tritiated folic acid by supernatants prepared from extracts of normal and leukaemic leucocytes, normal mucosa, and malignant tumours from different parts of the gastrointestinal tract has been measured using Sephadex-gel filtration and albumin-coated charcoal techniques. Non-specific binding (measured by Sephadex G-75 gel filtration) was almost invariably greater than specific binding measured by albumin-coated charcoal separation of bound and unbound folate. In nine normal leucocyte extracts, binding measured by Sephadex G-75 filtration ranged from 1.3 to 18.2 (mean 8.2) pg/mg protein and by albumin-coated charcoal from 1.0 to 14.8 (mean 6.7) pg/mg protein. Raised specific binding was found in the extracts from leucocytes of eight of 14 patients with chronic granulocytic leukaemia, in four substantially so (389, 121, 108, 59.7 pg/mg protein), but was only marginally increased in one of eight cases of acute myeloid leukaemia and in two of five cases of chronic lymphocytic leukaemia. Binding was normal in the extracts of all three cases of acute lymphoblastic leukaemia tested. Among the tissues of the gastrointestinal tract binding was greatest by the duodenal mucosa and liver. Extracts of carcinoma of the stomach and colon bound greater amounts of (3)H-folic acid than the corresponding normal mucosal extracts but the differences were not large. Sephadex G-200 gel chromatography showed more than one binding peak in the extracts of liver and duodenum but only one peak in the other tissues of the gastrointestinal tract, and only one peak, of molecular weight either about 50 000 or over 200 000, in the leucocyte extracts.

Folic acid binding protein in chronic granulocytic leukaemia: the effect of methotrexate.

Folic acid binding protein (FABP) has been measured in the supernatant of leukocytes of 12 patients affected with chronic granulocytic leukaemia (CGL). The folate binding capacity ranged from 1.37 to 697.52 pg/mg protein, showing a considerable heterogeneity. When the supernatant was preincubated with methotrexate (MTX), the inhibition of folic acid binding was complete in some cases whereas in others it was negligible: these findings have been confirmed by studying the 3H-MTX binding capacity by the same supernatants. In this case the range of bound 3H-HTX varied from 0.00 to 927 pg/mg protein. The presence of a binder in the cytoplasm of leukocytes might represent a new step in the regulation of endogenous folate metabolism. The MTX, widely used as an antifolate drug, may also be bound by FABP of CGL leukocytes, although in different amounts from case to case: this finding suggests a new point of interference of MTX in the folate metabolism. It has also been demonstrated that FABP, which is present in serum, may reduce the uptake of folate by leukocytes opening a new field of investigation on the megaloblastic transformation.